Aeterna Zentaris tanks on FDA Macrilen rejection

Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).